Neonatal abstinence syndrome (NAS) is a postnatal withdrawal syndrome resulting from in utero opioid exposure. NAS is characterized by central and autonomic nervous system hyperactivity. Skin excoriations are common secondary to neonatal agitation and motor hyperactivity. 1 Due to the increasing prevalence of opioid use in pregnancy in the United States, 2 the incidence of NAS has increased fivefold between 2004 and 2014 and continues to rise. [3][4][5] The increasing incidence has sparked interest in improving diagnosis and management.Currently, the Modified Finnegan Neonatal Abstinence Syndrome Tool (M-FNAST) is commonly used to diagnose disease and assess severity. The M-FNAST evaluates twenty-one observable NAS